Study wrapper · #847
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
Editor's note
Published in JAMA Psychiatry, this systematic review and network meta-analysis (95 studies, 39 interventions, pooled N=5,898) ranks drugs for antipsychotic-induced weight gain in schizophrenia-spectrum disorders — a clinically important, cardiometabolically high-risk problem. Semaglutide is directly evaluated and topped the list, associated with the largest weight reduction (−10.98 kg; 95% CI −13.33 to −8.62) at moderate certainty, and among the few agents reaching a clinically meaningful ≥5% change. That is a strong relative signal from a high-quality synthesis using CINeMA certainty grading. The load-bearing caveat is sparse direct data: the semaglutide estimate rests on just three trials (k=3), so the wide confidence interval reflects genuine uncertainty despite the moderate rating, and the population is specific. Reassuringly, the review reported no major excess of gastrointestinal dropout across interventions. Read this as credible, appropriately-hedged evidence that semaglutide is a leading option for weight in this population, grounded in few trials that warrant confirmation.
Plain-language abstract
Antipsychotic medications used for schizophrenia often cause significant weight gain, which raises the risk of diabetes and heart disease. This high-quality review combined 95 studies testing 39 different drugs (nearly 5,900 people total) to see which best reduce weight in people taking antipsychotics. Semaglutide came out on top, associated with the largest average weight loss (about 11 kg, or roughly 24 pounds), followed by liraglutide, topiramate, metformin, and exenatide — all supported by moderate-quality evidence. Semaglutide and metformin were among the agents producing a clinically meaningful weight change of 5% or more. The researchers found no major problems with stomach side effects or people dropping out across the different drugs. Important limit: the semaglutide result came from only three trials, so despite the encouraging ranking, there is real uncertainty and the finding needs confirmation in larger studies. The authors conclude these drugs, semaglutide in particular, offer useful options for clinicians managing weight gain caused by antipsychotics.